Grifols

We are proud to share that we have received the EcoVadis Gold Medal for the second year in a row. With a score of 77, we rank in the top 5% out of 100,000 companies assessed worldwide. 🌱 This recognition highlights our commitment to sustainability and ethical practices. Learn more here 👉 http://spr.ly/6044S5S3K #SustainableFuture #CorporateResponsibility #ESG

Continuing the walk through our history of innovation, we would like to stop in 1965, when Víctor Grifols i Lucas developed a new plasmapheresis centrifuge that made the plasma donation process more efficient and safer. In its early days, technical limitations meant that plasmapheresis was not as safe as it is today. The time needed to centrifuge the donation of whole blood was five or six hours, due in part to the centrifuging process being separate from the extraction process. This new centrifuge allowed plasmapheresis to be performed right next to the donor, and cells and platelets could be reinfused immediately after extraction. For the first time the three steps were efficiently integrated into one seamless process. The process allowed donors to donate more frequently, resulting in a wider and safer supply for plasma-derived medicines. Dive deep into our legacy of innovation 👉 http://spr.ly/6049SKa1x #Since1909

We are pleased to announce that we have received FDA approval for our fibrin sealant (FS) to control surgical bleeding in pediatric patients. Younger patients in the U.S. can now benefit from Grifols FS, including a fast time to hemostasis. Grifols FS biosurgery treatment is already approved for the younger patient population in Europe. It is distributed by Johnson & Johnson MedTech in the U.S., Canada, Europe and other markets as part of a strategic collaboration between the two companies. For more information, see the press release 👉 http://spr.ly/6045SJ8QN #WeAreInnovation #minimallyinvasivesurgery #PediatricSurgery

Today we want to focus on bees 🐝 🐝 🐝 What do they have in common with a healthcare company? Nothing and a lot. Plasma is as important for animals and humans, as bees are for preserving our planet. Their pollination activities are crucial for the reproduction of many food crops, directly impacting our food security. At Grifols, we support two impactful projects aimed at their preservation. In Dublin, Ireland, we've partnered with the Irish Bee Project to establish a bee sanctuary that nurtures local bee populations and promotes biodiversity. Meanwhile, in Clayton, N.C., U.S., volunteer employees have undergone training in beekeeping to care for hives located within a pollinator garden at our facilities. We want you to meet Brent McLeod, one of the initiators of this amazing project. #GrifolsWildlife #ClimateAction

We are pleased to announce that Dr. Quentin Riller officially received the ASPIRE Award 2024 from Prof. Alain Fischer at the European Society for Immunodeficiencies (ESID) 2024 Congress in Marseille. Dr. Riller, a distinguished investigator from the Institut Imagine & Université Paris Cité , was honored for his groundbreaking project titled “Enteric virus-associated hepatitis in patients with a defective antibody response (EVAHDAR) as a new immunopathological condition.” This innovative research aims to unravel the complexities of this liver disease in patients with antibody deficiencies, establishing a crucial link with chronic enteric virus infection. Dr. Riller’s work paves the way for future treatments and offers new insights into primary and secondary immunodeficiency diseases. Founded in 2021, the ASPIRE Award was established to identify and support innovative research projects that offer a greater insight into primary and secondary immunodeficiency diseases. Applications for the ASPIRE Award 2025 will be accepted from November 1st, 2024 👉 https://lnkd.in/dCbsHya #GrifolsScientificAwards #immunology #ESID2024

In our journey to achieve a low-carbon society and a healthier word, we are proud to announce that our near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi). Our specific and measurable actions to source, manufacture and consume more responsibly reinforce the environmental pillar of our sustainability strategy. Discover more 👉🏻 https://bit.ly/40gX083 #SustainableFuture #SBTi #climateaction

On #InternationalDayAgainstClimateChange, we want to share 6ways in which we are actively fighting against climate change. We strive to: ♻️ Keep reducing our waste, ☀️ Consume more renewable electric energy, 💧 Rationalize and better use water, 💨 Decarbonize our business trips and commuting, 🌳 Keep protecting biodiversity. 💨 Decarbonizing supply chain emissions. Our mission is to ensure a better and healthier future for everyone.

We are very pleased to host Catalonia.Health (CataloniaBio & HealthTech) Unconference 2024 – “Embracing Medical AI” – at our global headquarters.   This prestigious annual event brings together influential leaders in life sciences and the broader healthcare sector to share insights, promote collaboration and drive innovation in the industry.   Grifols, which applies AI and other advanced technologies to benefit patients, is the ideal forum to discuss and debate what the future of healthcare innovation will look like.   #UnconferenceAI #artificialintelligence #WeAreHealthcare

We are pleased to announce our partnership with the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) to test Grifols’ ocular surface immunoglobulin (OSIG) eye drops for treating sulfur mustard-induced eye injuries.   If the preclinical evaluation is successful, this initiative could lead to FDA approval, making it one of the first medical treatments available for exposure to sulfur mustard, also known as mustard gas.   We will develop a treatment for sulfur mustard ocular exposure by repurposing the investigational OSIG therapeutic currently in development for dry eye disease, which is expected start a phase 2 clinical trial in the first half of 2025.   For more information, see the press release 👉 https://bit.ly/3YeOhAH   #WeAreInnovation #Immunology

This year marks an exciting milestone for Grifols France, as we celebrate 25 years of success and innovation. Established in 1999, we’ve grown to become a key partner to the French healthcare system, contributing significantly to public health through our Diagnostic and Biopharma solutions. Today, with over 70 employees, we are proud of achievements like our strengthened partnership with Établissement Français du Sang, and the growth of our Biopharma offering. We thank our talented French team and strong partnerships for helping us reach this milestone. 🎉 Nous souhaitons que les années à venir soient pleines de progrès, d'innovation et d'impact positif. #GrifolsFrance #WeAreHealthcare